QURE

$21.798.71%-2.08

Uniqure Nv (QURE)

Date: O: H: L: C: Vol:

Precedente Chiudi:

$23.87

Aprire:

$24.10

Volume 24 ore:

989,730

Volume relativo:

0.52

Capitalizzazione di mercato:

$1.51B

Reddito:

$18.09M

Utile/perdita netta:

-$208.87M

Rapporto P/E:

EPS:

-$3.51

Flusso di cassa netto:

-$178.15M

1W Prestazione:

-12.74%

1M Prestazione:

-7.12%

6M Prestazione:

+5.37%

1Y Prestazione:

-28.42%

Intervallo 1D:

$21.51$24.22

Intervallo di 1 settimana:

$22.42$26.60

Portata 52W:

$8.73$51.72

Profilo aziendale di Uniqure Nv (QURE)

Nome

Uniqure Nv

Settore

Healthcare

Industria

Biotechnology

Telefono

1-339-970-7000

Indirizzo

PAASHEUVELWEG 25A, AMSTERDAM, Netherlands

Dipendente

221

@uniQure_NV

Prossima data di guadagno

2026-11-04

Ultimi documenti SEC

SEC

Discussioni di QURE su X

Cap. di mercato

Reddito

Reddito netto

Flusso di cassa

EPS

Uniqure Nv Azioni (QURE) Upgrade e downgrade

Data	Azione	Analista	Modifica della valutazione
2026-10-05	Downgrade	Barclays	Overweight → Equal Weight
2026-09-02	Resumed	William Blair	Outperform
2026-07-30	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2026-06-18	Aggiornamento	Barclays	Equal Weight → Overweight
2026-06-17	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2026-03-11	Aggiornamento	Mizuho	Neutral → Outperform
2026-03-09	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2026-03-09	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2026-03-03	Downgrade	Mizuho	Outperform → Neutral
2026-03-03	Downgrade	Wells Fargo	Overweight → Equal Weight
2026-03-02	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2026-03-02	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2026-02-24	Iniziato	Wolfe Research	Peer Perform
2026-01-28	Iniziato	Barclays	Equal Weight
2025-11-04	Downgrade	William Blair	Outperform → Mkt Perform
2025-08-14	Aggiornamento	Mizuho	Neutral → Outperform
2025-04-01	Resumed	Chardan Capital Markets	Buy
2024-12-10	Aggiornamento	Raymond James	Outperform → Strong Buy
2024-10-10	Resumed	Raymond James	Outperform
2024-02-29	Downgrade	Goldman	Buy → Neutral
2023-12-19	Downgrade	Mizuho	Buy → Neutral
2022-03-17	Aggiornamento	UBS	Neutral → Buy
2021-06-15	Iniziato	BTIG Research	Buy
2021-05-21	Iniziato	UBS	Neutral
2021-04-26	Resumed	Credit Suisse	Outperform
2021-04-01	Aggiornamento	Mizuho	Neutral → Buy
2021-01-07	Aggiornamento	Guggenheim	Neutral → Buy
2020-11-24	Iniziato	H.C. Wainwright	Buy
2020-11-11	Iniziato	Berenberg	Buy
2020-11-09	Iniziato	Jefferies	Buy
2020-11-04	Iniziato	Cantor Fitzgerald	Overweight
2020-10-23	Iniziato	RBC Capital Mkts	Outperform
2020-08-25	Iniziato	Raymond James	Strong Buy
2020-07-31	Aggiornamento	Robert W. Baird	Neutral → Outperform
2020-06-25	Downgrade	Mizuho	Buy → Neutral
2020-06-25	Downgrade	Robert W. Baird	Outperform → Neutral
2020-06-25	Downgrade	Wells Fargo	Overweight → Equal Weight
2019-12-03	Iniziato	Cowen	Outperform
2019-12-03	Iniziato	Goldman	Buy
2019-11-05	Iniziato	Credit Suisse	Outperform
2019-10-11	Iniziato	Stifel	Buy
2019-09-25	Iniziato	Bernstein	Outperform
2019-09-12	Iniziato	Mizuho	Buy
2019-07-30	Downgrade	Guggenheim	Buy → Neutral
2019-07-08	Reiterato	Cantor Fitzgerald	Overweight
2019-04-12	Iniziato	Piper Jaffray	Overweight
2019-03-29	Iniziato	Robert W. Baird	Outperform

Uniqure Nv Azioni (QURE) Dati Finanziari

Periodo	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Data di fine periodo	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	16.10	27.12	15.84	106.48	524.00
Cost of revenue USD (M)	1.69	1.27	0.07	1.25	24.98
Gross profit USD (M)	-	-	15.78	105.23	499.03
Research and development USD (M)	140.67	143.78	214.86	197.59	143.55
Operating expenses USD (M)	207.82	214.77	298.65	248.39	188.41
Operating income USD (M)	-185.35	-184.29	-282.87	-143.16	310.62
Income before tax USD (M)	-193.34	-237.13	-306.56	-128.26	332.81
Income tax expense USD (M)	5.63	2.43	1.92	-1.47	3.22
Net income USD (M)	-198.97	-239.56	-308.48	-126.79	329.59
Basic EPS USD/shares	-3.46	-4.92	-6.47	-2.71	7.17
Diluted EPS USD/shares	-3.46	-4.92	-6.47	-2.71	7.04
Basic weighted shares shares (M)	57.50	48.65	47.67	46.74	45.99
Diluted weighted shares shares (M)	57.50	48.65	47.67	46.74	46.84
Selling, general and administrative USD (M)	65.46	52.66	74.59	55.06	56.29

Uniqure Nv Azioni (QURE) insider trading

Kapusta Matthew CJul 02 '26
CEO, Managing Director
Transazione
Option Exercise
Costo
$19.39
#Azioni
21,082
Valore ($)
408,780
#Azioni Totale
540,309
Kapusta Matthew CJul 02 '26
CEO, Managing Director
Transazione
Sale
Costo
$45.16
#Azioni
21,082
Valore ($)
952,051
#Azioni Totale
519,227
Kapusta Matthew CJul 02 '26
Officer
Transazione
Proposed Sale
Costo
$45.15
#Azioni
21,082
Valore ($)
951,932
#Azioni Totale
0
Kaye JackJun 30 '26
Director
Transazione
Sale
Costo
$46.44
#Azioni
21,167
Valore ($)
983,030
#Azioni Totale
25,996
Abi-Saab WalidJun 30 '26
Chief Medical Officer
Transazione
Proposed Sale
Costo
$46.42
#Azioni
30,000
Valore ($)
1,392,643
#Azioni Totale
0
Kaye JackJun 30 '26
Director
Transazione
Proposed Sale
Costo
$46.44
#Azioni
21,167
Valore ($)
983,033
#Azioni Totale
0
Abi-Saab WalidJun 30 '26
Chief Medical Officer
Transazione
Option Exercise
Costo
$5.59
#Azioni
10,000
Valore ($)
55,900
#Azioni Totale
178,235
Abi-Saab WalidJun 30 '26
Chief Medical Officer
Transazione
Sale
Costo
$46.42
#Azioni
30,000
Valore ($)
1,392,600
#Azioni Totale
148,235
Kaye JackJun 30 '26
Director
Transazione
Option Exercise
Costo
$23.44
#Azioni
21,167
Valore ($)
496,230
#Azioni Totale
43,056
Abi-Saab WalidJun 26 '26
Chief Medical Officer
Transazione
Sale
Costo
$46.86
#Azioni
1,434
Valore ($)
67,197
#Azioni Totale
168,235

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Kapusta Matthew C	CEO, Managing Director	Jul 02 '26	Option Exercise	$19.39	21,082	408,780	540,309
Kapusta Matthew C	CEO, Managing Director	Jul 02 '26	Sale	$45.16	21,082	952,051	519,227
Kapusta Matthew C	Officer	Jul 02 '26	Proposed Sale	$45.15	21,082	951,932	0
Kaye Jack	Director	Jun 30 '26	Sale	$46.44	21,167	983,030	25,996
Abi-Saab Walid	Chief Medical Officer	Jun 30 '26	Proposed Sale	$46.42	30,000	1,392,643	0
Kaye Jack	Director	Jun 30 '26	Proposed Sale	$46.44	21,167	983,033	0
Abi-Saab Walid	Chief Medical Officer	Jun 30 '26	Option Exercise	$5.59	10,000	55,900	178,235
Abi-Saab Walid	Chief Medical Officer	Jun 30 '26	Sale	$46.42	30,000	1,392,600	148,235
Kaye Jack	Director	Jun 30 '26	Option Exercise	$23.44	21,167	496,230	43,056
Abi-Saab Walid	Chief Medical Officer	Jun 26 '26	Sale	$46.86	1,434	67,197	168,235

Uniqure Nv Borsa (QURE) Ultime notizie

Nov 03, 2026

All eyes on UniQure earnings amid pivotal Huntington’s therapy review - Investing.com

Nov 03, 2026

How uniQure's(NASDAQ:QURE) Huntington's Disease Gene Therapy Could Become the World's First Disease-Modifying Treatment - Kalkine

Nov 03, 2026

Nov 02, 2026

uniQure's Gene Therapy BLA for Huntington's Disease Gains FDA Pr - GuruFocus

Nov 02, 2026

FDA Opens Review of uniQure's Huntington's Gene Therapy, With May 2027 Verdict Date - BigGo Finance

Nov 02, 2026

FDA to review uniQure's Huntington's gene therapy, decision due on May 2027 - Reuters

Nov 02, 2026

uniQure Huntington’s Gene Therapy Wins FDA Priority Review, Analyst Bullish - uniQure (NASDAQ:QURE) - Benzinga

Nov 02, 2026

uniQure stock jumps as FDA accepts Huntington’s therapy filing - Investing.com

Nov 02, 2026

uniQure gains FDA priority review for Huntington's gene therapy - Mugglehead Investment Magazine

Nov 02, 2026

uniQure announces FDA acceptance, priority review for ifezuntirgene inilparvovec - TipRanks

Nov 02, 2026

FDA accepts uniQure’s Huntington’s disease gene therapy filing By Investing.com - Investing.com India

Nov 02, 2026

uniQure N.V. (UQ1.F) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Oct 30, 2026

3 Promising Genomics Stocks to Add to Your Portfolio Now - Zacks Investment Research

Oct 30, 2026

uniQure N.V. (UQ1.F) Seasonal returns chart - Yahoo Finance Australia

Oct 30, 2026

Oct 29, 2026

Earnings Preview: UniQure NV to Report Financial Results Pre-market on November 04 - Moomoo

Oct 29, 2026

uniQure N.V. (QURE) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Oct 29, 2026

Oct 28, 2026

uniQure to Announce Third Quarter 2026 Financial Results - GlobeNewswire

Oct 28, 2026

uniQure to Announce Third Quarter 2026 Financial Results - Yahoo Finance

Oct 28, 2026

Oct 23, 2026

uniQure N.V. Estimates – NASDAQ:QURE - TradingView

Oct 23, 2026

Oct 15, 2026

QURE Assumes Buy Rating by UBS -- Price Target Raised to $48 - GuruFocus

Oct 15, 2026

UBS Adjusts Price Target on uniQure to $48 From $27, Maintains Buy Rating - marketscreener.com

Oct 15, 2026

uniQure: The Market Graded The Wrong Exam (NASDAQ:QURE) - Seeking Alpha

Oct 15, 2026

UBS Adjusts Price Target on uniQure to $48 From $27, Maintains Buy Rating - Yahoo Finance

Oct 15, 2026

Oct 13, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT - GlobeNewswire Inc.

Oct 13, 2026

Oct 12, 2026

uniQure NV (UQ1.SG) Analyst Insights, Price Targets & Recommendations - Yahoo Finance - Yahoo! Finance Canada

Oct 12, 2026

Oct 08, 2026

uniQure N.V. (QURE) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore

Oct 08, 2026

Oct 07, 2026

Why uniQure (QURE) Is Down 5.9% After Fresh Huntington’s Gene Therapy Data Update And What’s Next - Yahoo Finance

Oct 07, 2026

Oct 06, 2026

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE) - Simply Wall Street

Oct 06, 2026

UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop - Business Wire

Oct 06, 2026

uniQure N.V. (QURE) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review

Oct 06, 2026

Oct 05, 2026

UniQure Shares Fall After Barclays Downgrade - marketscreener.com

Oct 05, 2026

Barclays Downgrades UniQure to Equal Weight From Overweight - Moomoo

Oct 05, 2026

Oct 02, 2026

Uniqure N.v Stock Price Forecast. Should You Buy QURE? - StockInvest.us

Oct 02, 2026

Oct 01, 2026

Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy - STAT

Oct 01, 2026

$uniQure NV (QURE.US)$ - Moomoo

Oct 01, 2026

Sep 30, 2026

UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire

Sep 30, 2026

UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire Inc.

Sep 30, 2026

uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update - Seeking Alpha

Sep 30, 2026

uniQure Plunges on Additional Data From Huntington's Disease Study - Zacks Investment Research

Sep 30, 2026

uniQure Plunges on Additional Data From Huntington's Disease Study - Yahoo Finance

Sep 30, 2026

uniQure Stock Plunges On 4-Year Data, But The Approval Path Is Intact (Rating Upgrade) - Seeking Alpha

Sep 30, 2026

EBITDA of uniQure N.V. – HAN:UQ1 - TradingView

Sep 30, 2026

Return on invested capital % of uniQure N.V. – HAN:UQ1 - TradingView

Sep 30, 2026

Sep 29, 2026

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - Morningstar

Sep 29, 2026

Four-year data raise durability questions for uniQure’s Huntington gene therapy - biocentury.com

Sep 29, 2026

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - PR Newswire

Sep 29, 2026

Simile a QURE

Uniqure Nv (QURE)

Profilo aziendale di Uniqure Nv (QURE)

Cap. di mercato

Reddito

Reddito netto

Flusso di cassa

EPS

Uniqure Nv Azioni (QURE) Upgrade e downgrade

Uniqure Nv Azioni (QURE) Dati Finanziari

Uniqure Nv Azioni (QURE) insider trading

Uniqure Nv Borsa (QURE) Ultime notizie

All eyes on UniQure earnings amid pivotal Huntington’s therapy review - Investing.com

How uniQure's(NASDAQ:QURE) Huntington's Disease Gene Therapy Could Become the World's First Disease-Modifying Treatment - Kalkine

uniQure's Gene Therapy BLA for Huntington's Disease Gains FDA Pr - GuruFocus

FDA Opens Review of uniQure's Huntington's Gene Therapy, With May 2027 Verdict Date - BigGo Finance

FDA to review uniQure's Huntington's gene therapy, decision due on May 2027 - Reuters

uniQure Huntington’s Gene Therapy Wins FDA Priority Review, Analyst Bullish - uniQure (NASDAQ:QURE) - Benzinga

uniQure stock jumps as FDA accepts Huntington’s therapy filing - Investing.com

uniQure gains FDA priority review for Huntington's gene therapy - Mugglehead Investment Magazine

uniQure announces FDA acceptance, priority review for ifezuntirgene inilparvovec - TipRanks

FDA accepts uniQure’s Huntington’s disease gene therapy filing By Investing.com - Investing.com India

Form 8K uniQure N.V. For: 2 November By Investing.com - Investing.com Canada

uniQure Announces FDA Acceptance and Priority Review of the - GlobeNewswire

uniQure N.V. (QURE) Stock Price, News, Quote & History - Yahoo! Finance Canada

uniQure N.V. (QURE) Seasonal returns chart - Yahoo Finance UK

uniQure N.V. (UQ1.F) Seasonal returns chart - Yahoo Finance UK

uniQure N.V. (UQ1.F) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

3 Promising Genomics Stocks to Add to Your Portfolio Now - Zacks Investment Research

uniQure N.V. (UQ1.F) Seasonal returns chart - Yahoo Finance Australia

Earnings Preview: UniQure NV to Report Financial Results Pre-market on November 04 - Moomoo

uniQure N.V. (QURE) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

uniQure to Announce Third Quarter 2026 Financial Results - GlobeNewswire

uniQure to Announce Third Quarter 2026 Financial Results - Yahoo Finance

uniQure N.V. Estimates – NASDAQ:QURE - TradingView

QURE Assumes Buy Rating by UBS -- Price Target Raised to $48 - GuruFocus

UBS Adjusts Price Target on uniQure to $48 From $27, Maintains Buy Rating - marketscreener.com

uniQure: The Market Graded The Wrong Exam (NASDAQ:QURE) - Seeking Alpha

UBS Adjusts Price Target on uniQure to $48 From $27, Maintains Buy Rating - Yahoo Finance

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT - GlobeNewswire Inc.

uniQure NV (UQ1.SG) Analyst Insights, Price Targets & Recommendations - Yahoo Finance - Yahoo! Finance Canada

uniQure N.V. (QURE) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore

Why uniQure (QURE) Is Down 5.9% After Fresh Huntington’s Gene Therapy Data Update And What’s Next - Yahoo Finance

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE) - Simply Wall Street

UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop - Business Wire

uniQure N.V. (QURE) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review

UniQure Shares Fall After Barclays Downgrade - marketscreener.com

Barclays Downgrades UniQure to Equal Weight From Overweight - Moomoo

Uniqure N.v Stock Price Forecast. Should You Buy QURE? - StockInvest.us

Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy - STAT

$uniQure NV (QURE.US)$ - Moomoo

UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire

UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire Inc.

uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update - Seeking Alpha

uniQure Plunges on Additional Data From Huntington's Disease Study - Zacks Investment Research

uniQure Plunges on Additional Data From Huntington's Disease Study - Yahoo Finance

uniQure Stock Plunges On 4-Year Data, But The Approval Path Is Intact (Rating Upgrade) - Seeking Alpha

EBITDA of uniQure N.V. – HAN:UQ1 - TradingView

Return on invested capital % of uniQure N.V. – HAN:UQ1 - TradingView

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - Morningstar

Four-year data raise durability questions for uniQure’s Huntington gene therapy - biocentury.com

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - PR Newswire

Simile a QURE